Symbols / KRYS Stock $274.03 +2.23% Krystal Biotech, Inc.

Healthcare • Biotechnology • United States • NMS
KRYS (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Krish S. Krishnan M.B.A., M.S.
Exch · Country NMS · United States
Market Cap 8.07B
Enterprise Value 7.02B
Income 204.83M
Sales 389.13M
FCF (ttm) 93.93M
Book/sh 41.78
Cash/sh 28.32
Employees 295
Insider 10d —
IPO Sep 20, 2017
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 40.12
Forward P/E 26.88
PEG —
P/S 20.73
P/B 6.56
P/C —
EV/EBITDA 43.07
EV/Sales 18.03
Quick Ratio 9.28
Current Ratio 9.95
Debt/Eq 0.77
LT Debt/Eq —
EPS (ttm) 6.83
EPS next Y 10.20
EPS Growth 11.60%
Revenue Growth 17.50%
EPS Gr Q/Q 13.00%
Rev Gr Q/Q —
Earnings (next) 2026-05-04
Earnings (prior) 2026-02-17
ROA 8.44%
ROE 18.91%
ROIC —
Gross Margin 94.08%
Oper. Margin 41.33%
Profit Margin 52.64%
Shs Outstand 29.44M
Shs Float 23.16M
Insider Own 11.41%
Instit Own 98.66%
Short Float 17.51%
Short Ratio 11.08
Short Interest 3.14M
52W High 298.30
vs 52W High -8.14%
52W Low 122.80
vs 52W Low 123.15%
Beta 0.54
Impl. Vol. 54.60%
Rel Volume 0.62
Avg Volume 280.40K
Volume 172.65K
Target (mean) $315.00
Tgt Median $310.00
Tgt Low $241.00
Tgt High $380.00
# Analysts 9
Recom Strong_buy
Prev Close $268.04
Price $274.03
Change 2.23%
About

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$315.00
Mean price target
2. Current target
$274.03
Latest analyst target
3. DCF / Fair value
$57.44
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$274.03
Low
$241.00
High
$380.00
Mean
$315.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-27 init Wolfe Research — → Peer Perform —
2026-02-25 main Guggenheim Buy → Buy $284
2026-02-18 main Citigroup Buy → Buy $371
2026-02-18 main Chardan Capital Buy → Buy $323
2026-02-17 main Jefferies Buy → Buy $371
2026-02-02 main Goldman Sachs Buy → Buy $327
2026-01-22 main B of A Securities Buy → Buy $318
2026-01-12 main Citigroup Buy → Buy $336
2026-01-09 main TD Cowen Buy → Buy $306
2026-01-09 main Citigroup Buy → Buy $320
2026-01-09 reit HC Wainwright & Co. Buy → Buy $310
2026-01-06 up Citigroup Neutral → Buy $309
2025-11-04 main Citigroup Neutral → Neutral $198
2025-11-04 main Chardan Capital Buy → Buy $220
2025-10-17 main B of A Securities Buy → Buy $255
2025-09-15 reit HC Wainwright & Co. Buy → Buy $240
2025-08-22 main Chardan Capital Buy → Buy $216
2025-08-22 reit HC Wainwright & Co. Buy → Buy $240
2025-08-05 main Citigroup Neutral → Neutral $166
2025-08-05 main Chardan Capital Buy → Buy $219
News
RSS: Latest KRYS news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-04 KRISHNAN SUMA M Officer, Director and Beneficial Owner — 25,000 $257.32 $6,580,270
2026-03-04 KRISHNAN KRISH S Chief Executive Officer — 25,000 $257.31 $6,579,164
2026-03-02 ROMANO KATHRYN Officer — 750 $267.60 $200,700
2026-02-27 JANNEY DANIEL SPENCER Director — 11,803 $275.45 $3,252,824
2026-02-27 KRISHNAN SUMA M Officer, Director and Beneficial Owner — 67,225 — —
2026-02-27 KRISHNAN KRISH S Chief Executive Officer — 67,225 — —
2026-02-27 ROMANO KATHRYN Officer — 8,050 — —
2026-02-26 JANNEY DANIEL SPENCER Director — 60,161 $262.91 $16,149,383
2026-02-24 JANNEY DANIEL SPENCER Director — 37,895 $2.46 $93,222
2026-02-19 ROSSI DINO A Director — 18,950 $260.49 $4,953,694
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
389.13
+33.94%
290.51
+473.02%
50.70
0.00
Operating Revenue
389.13
+33.94%
290.51
+473.02%
50.70
0.00
Cost Of Revenue
23.05
+14.89%
20.06
+548.38%
3.09
0.00
Reconciled Cost Of Revenue
23.05
+14.89%
20.06
+548.38%
3.09
0.00
Gross Profit
366.08
+35.36%
270.45
+468.12%
47.60
0.00
Operating Expense
204.79
+22.48%
167.21
+15.54%
144.72
+20.41%
120.20
Research And Development
58.05
+8.33%
53.58
+15.39%
46.43
+9.35%
42.46
Selling General And Administration
146.74
+29.14%
113.63
+15.60%
98.29
+26.44%
77.73
General And Administrative Expense
—
—
—
77.73
Other Gand A
—
—
—
77.73
Total Expenses
227.84
+21.66%
187.27
+26.69%
147.82
+22.98%
120.20
Operating Income
161.29
+56.22%
103.25
+206.31%
-97.12
+19.20%
-120.20
Total Operating Income As Reported
161.29
+145.32%
65.75
+159.98%
-109.62
+24.50%
-145.20
EBITDA
167.85
+52.64%
109.96
+220.56%
-91.21
+21.92%
-116.81
Normalized EBITDA
167.85
+13.82%
147.46
+182.52%
-178.71
-94.65%
-91.81
Reconciled Depreciation
6.55
-2.43%
6.71
+13.58%
5.91
+74.62%
3.38
EBIT
161.29
+56.22%
103.25
+206.31%
-97.12
+19.20%
-120.20
Total Unusual Items
0.00
+100.00%
-37.50
-142.86%
87.50
+450.00%
-25.00
Total Unusual Items Excluding Goodwill
0.00
+100.00%
-37.50
-142.86%
87.50
+450.00%
-25.00
Special Income Charges
0.00
+100.00%
-37.50
-142.86%
87.50
+450.00%
-25.00
Other Special Charges
—
37.50
+142.86%
-87.50
-450.00%
25.00
Net Income
204.83
+129.74%
89.16
+715.58%
10.93
+107.81%
-139.97
Pretax Income
189.47
+98.70%
95.36
+639.37%
12.90
+109.21%
-139.97
Net Non Operating Interest Income Expense
28.18
-4.84%
29.61
+31.51%
22.51
+331.22%
5.22
Interest Expense Non Operating
—
—
0.00
0.00
Net Interest Income
28.18
-4.84%
29.61
+31.51%
22.51
+331.22%
5.22
Interest Expense
—
—
0.00
0.00
Interest Income Non Operating
28.18
-4.84%
29.61
+31.51%
22.51
+331.22%
5.22
Interest Income
28.18
-4.84%
29.61
+31.51%
22.51
+331.22%
5.22
Other Income Expense
—
-37.50
-142.86%
87.50
+450.00%
-25.00
Tax Provision
-15.36
-347.86%
6.20
+215.37%
1.97
0.00
Tax Rate For Calcs
0.00
+223.14%
0.00
-57.35%
0.00
0.00
Tax Effect Of Unusual Items
0.00
+100.00%
-2.44
-118.28%
13.33
0.00
Net Income Including Noncontrolling Interests
204.83
+129.74%
89.16
+715.58%
10.93
+107.81%
-139.97
Net Income From Continuing Operation Net Minority Interest
204.83
+129.74%
89.16
+715.58%
10.93
+107.81%
-139.97
Net Income From Continuing And Discontinued Operation
204.83
+129.74%
89.16
+715.58%
10.93
+107.81%
-139.97
Net Income Continuous Operations
204.83
+129.74%
89.16
+715.58%
10.93
+107.81%
-139.97
Normalized Income
204.83
+64.89%
124.22
+296.44%
-63.24
+45.00%
-114.97
Net Income Common Stockholders
204.83
+129.74%
89.16
+715.58%
10.93
+107.81%
-139.97
Diluted EPS
6.84
+128.00%
3.00
+669.23%
0.39
+107.10%
-5.49
Basic EPS
7.08
+126.92%
3.12
+680.00%
0.40
+107.29%
-5.49
Basic Average Shares
28.94
+1.23%
28.59
+5.30%
27.15
+6.52%
25.49
Diluted Average Shares
29.95
+0.71%
29.74
+7.16%
27.75
+8.87%
25.49
Diluted NI Availto Com Stockholders
204.83
+129.74%
89.16
+715.58%
10.93
+107.81%
-139.97
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
1,333.79
+26.33%
1,055.84
+29.02%
818.36
+46.54%
558.45
Current Assets
1,024.60
+38.08%
742.04
+26.22%
587.91
+53.19%
383.78
Cash Cash Equivalents And Short Term Investments
827.79
+38.54%
597.52
+12.28%
532.18
+40.35%
379.17
Cash And Cash Equivalents
496.30
+43.91%
344.87
-3.76%
358.33
+121.33%
161.90
Other Short Term Investments
331.49
+31.20%
252.65
+45.33%
173.85
-19.98%
217.27
Receivables
127.42
+21.65%
104.75
+149.16%
42.04
0.00
Accounts Receivable
127.42
+21.65%
104.75
+149.16%
42.04
0.00
Inventory
40.48
+52.69%
26.51
+279.50%
6.99
0.00
Raw Materials
15.94
+16.86%
13.64
+332.44%
3.15
0.00
Work In Process
15.22
+41.71%
10.74
+235.30%
3.20
0.00
Finished Goods
9.31
+338.05%
2.13
+239.07%
0.63
0.00
Prepaid Assets
14.01
+766.17%
1.62
—
—
Other Current Assets
14.90
+27.86%
11.66
+73.83%
6.71
+45.53%
4.61
Total Non Current Assets
309.19
-1.47%
313.79
+36.17%
230.45
+31.93%
174.67
Net PPE
158.01
-2.13%
161.45
-4.03%
168.23
-0.88%
169.73
Gross PPE
189.30
+3.23%
183.37
+1.28%
181.06
+2.57%
176.52
Accumulated Depreciation
-31.28
-42.71%
-21.92
-70.88%
-12.83
-88.83%
-6.79
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
109.24
-1.98%
111.44
+0.24%
111.18
0.00
Machinery Furniture Equipment
4.71
+22.43%
3.85
+18.55%
3.25
+207.10%
1.06
Construction In Progress
8.11
+40.33%
5.78
-20.75%
7.29
-94.45%
131.33
Other Properties
40.01
+9.24%
36.62
+6.87%
34.27
+72.10%
19.91
Leases
27.23
+6.05%
25.67
+2.41%
25.07
+3.51%
24.22
Investments And Advances
128.07
-15.81%
152.11
+145.53%
61.95
+1240.71%
4.62
Other Investments
—
—
—
4.62
Non Current Deferred Assets
22.82
0.00
—
—
Non Current Deferred Taxes Assets
22.82
0.00
—
—
Other Non Current Assets
0.29
+24.24%
0.23
-12.17%
0.26
-18.83%
0.32
Total Liabilities Net Minority Interest
114.23
+4.36%
109.46
+175.62%
39.71
+9.65%
36.22
Current Liabilities
102.94
+0.93%
102.00
+208.20%
33.09
+14.72%
28.85
Payables And Accrued Expenses
97.59
-0.80%
98.38
+234.37%
29.42
+8.89%
27.02
Payables
14.16
+52.67%
9.27
+52.22%
6.09
+51.39%
4.02
Accounts Payable
3.24
-35.05%
4.99
+20.64%
4.13
+3.79%
3.98
Current Accrued Expenses
83.44
-6.36%
89.10
+281.94%
23.33
+1.45%
23.00
Total Tax Payable
10.92
+154.64%
4.29
+118.78%
1.96
+4458.14%
0.04
Current Debt And Capital Lease Obligation
1.77
+45.52%
1.22
-17.44%
1.47
-5.57%
1.56
Current Capital Lease Obligation
1.77
+45.52%
1.22
-17.44%
1.47
-5.57%
1.56
Other Current Liabilities
3.58
+48.94%
2.40
+9.28%
2.20
+723.60%
0.27
Total Non Current Liabilities Net Minority Interest
11.29
+51.31%
7.46
+12.73%
6.62
-10.20%
7.37
Long Term Debt And Capital Lease Obligation
7.57
+25.22%
6.04
-8.70%
6.62
-10.20%
7.37
Long Term Capital Lease Obligation
7.57
+25.22%
6.04
-8.70%
6.62
-10.20%
7.37
Other Non Current Liabilities
3.72
+162.44%
1.42
—
—
Stockholders Equity
1,219.56
+28.87%
946.38
+21.54%
778.64
+49.10%
522.23
Common Stock Equity
1,219.56
+28.87%
946.38
+21.54%
778.64
+49.10%
522.23
Capital Stock
0.00
0.00
0.00
0.00
Common Stock
0.00
0.00
0.00
0.00
Preferred Stock
—
—
—
—
Share Issued
29.19
+1.38%
28.79
+1.97%
28.24
+9.60%
25.76
Ordinary Shares Number
29.19
+1.38%
28.79
+1.97%
28.24
+9.60%
25.76
Additional Paid In Capital
1,194.26
+5.95%
1,127.24
+7.58%
1,047.83
+30.37%
803.72
Retained Earnings
24.16
+113.37%
-180.67
+33.04%
-269.83
+3.89%
-280.76
Gains Losses Not Affecting Retained Earnings
1.14
+697.89%
-0.19
-129.78%
0.64
+187.64%
-0.73
Other Equity Adjustments
1.14
+697.89%
-0.19
-129.78%
0.64
+187.64%
-0.73
Total Equity Gross Minority Interest
1,219.56
+28.87%
946.38
+21.54%
778.64
+49.10%
522.23
Total Capitalization
1,219.56
+28.87%
946.38
+21.54%
778.64
+49.10%
522.23
Working Capital
921.66
+44.00%
640.05
+15.36%
554.82
+56.32%
354.93
Invested Capital
1,219.56
+28.87%
946.38
+21.54%
778.64
+49.10%
522.23
Total Debt
9.34
+28.62%
7.26
-10.29%
8.09
-9.39%
8.93
Capital Lease Obligations
9.34
+28.62%
7.26
-10.29%
8.09
-9.39%
8.93
Net Tangible Assets
1,219.56
+28.87%
946.38
+21.54%
778.64
+49.10%
522.23
Tangible Book Value
1,219.56
+28.87%
946.38
+21.54%
778.64
+49.10%
522.23
Available For Sale Securities
128.07
-15.81%
152.11
+145.53%
61.95
+1240.71%
4.62
Investmentin Financial Assets
128.07
-15.81%
152.11
+145.53%
61.95
+1240.71%
4.62
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
200.87
+62.75%
123.42
+238.98%
-88.80
+11.70%
-100.57
Cash Flow From Continuing Operating Activities
200.87
+62.75%
123.42
+238.98%
-88.80
+11.70%
-100.57
Net Income From Continuing Operations
204.83
+129.74%
89.16
+715.58%
10.93
+107.81%
-139.97
Depreciation Amortization Depletion
6.55
-2.43%
6.71
+13.58%
5.91
+74.62%
3.38
Depreciation
6.55
-2.43%
6.71
+13.58%
5.91
+74.62%
3.38
Depreciation And Amortization
6.55
-2.43%
6.71
+13.58%
5.91
+74.62%
3.38
Other Non Cash Items
0.68
+4.91%
0.65
+200.46%
0.22
+538.24%
0.03
Stock Based Compensation
54.51
+10.97%
49.13
+23.02%
39.93
+20.17%
33.23
Deferred Tax
-22.84
0.00
0.00
—
Deferred Income Tax
-22.84
0.00
0.00
—
Operating Gains Losses
-5.95
+1.91%
-6.07
+94.23%
-105.09
-18337.19%
-0.57
Gain Loss On Investment Securities
-5.95
+1.91%
-6.07
-19.19%
-5.09
-793.33%
-0.57
Unrealized Gain Loss On Investment Securities
—
—
-5.09
-793.33%
-0.57
Gain Loss On Sale Of PPE
—
—
0.03
-62.50%
0.07
Change In Working Capital
-36.42
-151.91%
-14.46
+62.47%
-38.52
-1549.83%
2.66
Change In Receivables
-22.12
+64.72%
-62.71
-49.16%
-42.04
0.00
Changes In Account Receivables
-22.12
+64.72%
-62.71
-49.16%
-42.04
0.00
Change In Inventory
-6.29
+47.21%
-11.91
-166.08%
-4.47
0.00
Change In Prepaid Assets
-14.66
-64.54%
-8.91
-452.67%
-1.61
-162.11%
-0.61
Change In Payables And Accrued Expense
4.95
-92.77%
68.48
+556.31%
10.43
+166.24%
3.92
Change In Accrued Expense
4.12
-93.89%
67.47
+540.42%
10.54
+103.65%
5.17
Change In Payable
0.83
-18.30%
1.01
+1100.99%
-0.10
+91.95%
-1.25
Change In Account Payable
0.83
-18.30%
1.01
+1100.99%
-0.10
+91.95%
-1.25
Change In Other Current Assets
—
—
-0.06
+57.33%
-0.15
Change In Other Current Liabilities
1.70
+190.44%
0.59
+170.69%
-0.83
-28.13%
-0.65
Investing Cash Flow
-58.42
+64.26%
-163.44
-297.78%
82.64
+172.44%
-114.08
Cash Flow From Continuing Investing Activities
-58.42
+64.26%
-163.44
-297.78%
82.64
+172.44%
-114.08
Net PPE Purchase And Sale
-11.95
-182.00%
-4.24
+64.08%
-11.80
+77.73%
-52.98
Purchase Of PPE
-11.95
-182.00%
-4.24
+64.08%
-11.80
+77.73%
-52.98
Capital Expenditure
-11.95
-182.00%
-4.24
+64.08%
-11.80
+77.73%
-52.98
Net Investment Purchase And Sale
-46.90
+70.54%
-159.20
-2761.78%
-5.56
+90.90%
-61.10
Purchase Of Investment
-422.54
+7.69%
-457.74
+10.03%
-508.78
-59.60%
-318.78
Sale Of Investment
375.64
+25.83%
298.54
-40.67%
503.21
+95.29%
257.68
Net Other Investing Changes
0.43
—
100.00
—
Financing Cash Flow
8.71
-67.78%
27.01
-86.68%
202.75
+473.60%
35.35
Cash Flow From Continuing Financing Activities
8.71
-67.78%
27.01
-86.68%
202.75
+473.60%
35.35
Net Common Stock Issuance
0.00
0.00
-100.00%
159.73
+451.01%
28.99
Proceeds From Stock Option Exercised
22.66
-30.06%
32.40
-25.98%
43.77
+524.61%
7.01
Net Other Financing Charges
-13.96
-159.12%
-5.39
-619.09%
-0.75
-15.41%
-0.65
Changes In Cash
151.15
+1262.27%
-13.01
-106.62%
196.58
+209.64%
-179.31
Effect Of Exchange Rate Changes
0.29
+162.45%
-0.46
-193.59%
-0.16
-280.49%
-0.04
Beginning Cash Position
344.87
-3.76%
358.33
+121.33%
161.90
-52.56%
341.25
End Cash Position
496.30
+43.91%
344.87
-3.76%
358.33
+121.33%
161.90
Free Cash Flow
188.91
+58.51%
119.18
+218.47%
-100.60
+34.48%
-153.55
Income Tax Paid Supplemental Data
15.67
+176.66%
5.67
0.00
0.00
Amortization Of Securities
-0.50
+70.81%
-1.71
+21.85%
-2.18
-425.82%
0.67
Common Stock Issuance
0.00
0.00
-100.00%
159.73
+451.01%
28.99
Issuance Of Capital Stock
0.00
0.00
-100.00%
159.73
+451.01%
28.99
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category